Neurocrine Biosciences, Inc. (NASDAQ:NBIX) develops therapies targeting neurological, neuroendocrine, and neuropsychiatric ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best strong buy healthcare stocks to buy now. On July 22, Morgan ...

Neurocrine Biosciences (NBIX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports ...

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best option ...

Neurocrine Biosciences has presented new one-year data from its Phase III CAHtalyst Adult study of Crenessity (crinecerfont) for classic congenital adrenal hyperplasia (CAH). The data revealed that ...

Neurocrine Biosciences (NASDAQ: NBIX) is set to give its latest quarterly earnings report on Monday, 2025-05-05. Here's what investors need to know before the announcement.

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options.

In the last 3 months, 15 analysts have offered 12-month price targets for Neurocrine Biosciences. The company has an average price target of $123.0 with a high of $150.00 and a low of $106.00.

According to 12 analyst offering 12-month price targets in the last 3 months, Neurocrine Biosciences has an average price target of $124.0 with a high of $140.00 and a low of $95.00.

Neurocrine Biosciences needs a clinical win after years of disappointing results and stagnant stock performance. The upcoming Phase III data on crinecerfont, a treatment for congenital adrenal ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.

About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs.